دورية أكاديمية
Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China
| العنوان: | Cost-effectiveness analysis of sorafenib, lenvatinib, atezolizumab plus bevacizumab and sintilimab plus bevacizumab for the treatment of advanced hepatocellular carcinoma in China |
|---|---|
| المؤلفون: | Gong, HongyuAff1, Aff2, Ong, Siew ChinAff1, IDs1296202300435x_cor2, Li, FanAff2, Aff6, Weng, Zhiying, Zhao, Keying, Jiang, Zhengyou |
| المصدر: | Cost Effectiveness and Resource Allocation. 21(1) |
| قاعدة البيانات: | Springer Nature Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 14787547 |
|---|---|
| DOI: | 10.1186/s12962-023-00435-x |